Type 2 diabetes mellitus
Endocrine · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Progressive hyperglycaemia from insulin resistance and beta-cell failure, strongly linked to obesity and (in South Asians) central adiposity at lower BMI. Management now prioritises cardiovascular and renal protection alongside glucose control.
Red flags
- Admit: HHS, DKA (uncommon), severe infection/sepsis, diabetic foot with ischaemia/spreading infection
- Refer: suspected T1DM/MODY, pregnancy/preconception, renal decline, uncontrolled despite triple therapy, recurrent severe hypos
Assessment
Investigations
- HbA1c (confirm diagnosis and track), fasting lipids, U&E and eGFR, urine ACR, LFTs
- Annual: retinal screening, foot exam, ACR
- Exclude secondary causes if atypical;
- GAD/anti-IA2 antibodies and C-peptide if T1DM/LADA suspected
Management
- Lifestyle + metformin first line
- Add SGLT2 inhibitor (empagliflozin/dapagliflozin) if CVD, heart failure or CKD
- GLP-1 RA (semaglutide, dulaglutide) if high CV risk or obesity
- Then DPP-4i, pioglitazone, sulfonylurea; insulin when oral agents inadequate
- BP target <140/90 (<130/80 if ACR raised), statin per QRISK, atorvastatin 20mg primary prevention
Disposition
Admit: HHS, DKA (uncommon), severe infection/sepsis, diabetic foot with ischaemia/spreading infection.
Complications & pitfalls
- Microvascular: retinopathy, nephropathy, neuropathy, diabetic foot
- Macrovascular: MI, stroke, peripheral arterial disease
- Acute: HHS, hypoglycaemia (treatment-related)
- Erectile dysfunction, increased infection risk
Exam pearls
- Start an SGLT2 inhibitor for heart failure or CKD even when HbA1c is at target; the benefit is largely glucose- independent. In South Asians, screen at lower BMI thresholds (overweight >=23 kg/m2).
- Monitoring & follow-up: HbA1c 3-6 monthly until stable then 6-monthly; individualise target (48-58 mmol/mol). Annual retinal screening, foot risk assessment, urine ACR, eGFR, lipids, BP. Review drug adherence, hypo awareness, injection sites.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.